Literature DB >> 25518007

Cardiovascular dysfunction in adult mice following postnatal intermittent hypoxia.

Alison Chu1, David Gozal1, Rene Cortese1, Yang Wang1.   

Abstract

BACKGROUND: Ex-premature infants are at higher risk for hypertension and cardiovascular disease as adults, although the mechanisms underlying such increased risks are unknown. We hypothesize that postnatal exposure to intermittent hypoxia (IH) leads to cardiovascular dysfunction in adulthood with alterations of the renin-angiotensin pathway.
METHODS: Neonatal mice were exposed to IH for 4 wk. At the age of 3 mo, various cardiovascular measurements were obtained.
RESULTS: IH-exposed mice exhibited higher systolic blood pressure, impaired baroreflex responses, and decreased heart rate variability. Furthermore, IH-exposed mice manifested evidence of endothelial dysfunction, as shown by reduced reperfusion indices after tail vessel occlusion and impaired vasodilatory responses to acetylcholine. CD31(+) endothelial cells isolated from mesenteric arteries of IH-exposed mice expressed higher levels of angiotensin-converting enzyme and reactive oxygen species; plasma angiotensin-II levels were also significantly higher in these animals. In addition, DNA methylation patterns of the Ace1 and the Agt genes in these cells were congruent with their expression patterns.
CONCLUSION: Our results suggest that exposures to postnatal IH alter the normal development of the renin-angiotensin system and promote the occurrence of cardiovascular dysfunction during adulthood in mice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25518007     DOI: 10.1038/pr.2014.197

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

Review 1.  The Epigenetic Machinery in Vascular Dysfunction and Hypertension.

Authors:  Emile Levy; Schohraya Spahis; Jean-Luc Bigras; Edgard Delvin; Jean-Michel Borys
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

Review 2.  DNA methylation markers in obesity, metabolic syndrome, and weight loss.

Authors:  Mirian Samblas; Fermín I Milagro; Alfredo Martínez
Journal:  Epigenetics       Date:  2019-03-27       Impact factor: 4.528

Review 3.  Circulating exosomes in obstructive sleep apnea as phenotypic biomarkers and mechanistic messengers of end-organ morbidity.

Authors:  Abdelnaby Khalyfa; Leila Kheirandish-Gozal; David Gozal
Journal:  Respir Physiol Neurobiol       Date:  2017-07-01       Impact factor: 1.931

4.  Early postnatal exposure to intermittent hypoxia in rodents is proinflammatory, impairs white matter integrity, and alters brain metabolism.

Authors:  Robert A Darnall; Xi Chen; Krishnamurthy V Nemani; Chrystelle M Sirieix; Barjor Gimi; Susan Knoblach; Betty L McEntire; Carl E Hunt
Journal:  Pediatr Res       Date:  2017-05-03       Impact factor: 3.756

Review 5.  A Comparison of Pathophysiology in Humans and Rodent Models of Subarachnoid Hemorrhage.

Authors:  Jenna L Leclerc; Joshua M Garcia; Matthew A Diller; Anne-Marie Carpenter; Pradip K Kamat; Brian L Hoh; Sylvain Doré
Journal:  Front Mol Neurosci       Date:  2018-03-22       Impact factor: 5.639

6.  Effects of early- and mid-life stress on DNA methylation of genes associated with subclinical cardiovascular disease and cognitive impairment: a systematic review.

Authors:  Elena M Vidrascu; Alexander C Bashore; Timothy D Howard; Justin B Moore
Journal:  BMC Med Genet       Date:  2019-03-12       Impact factor: 2.103

7.  The Placental Transcriptome in Late Gestational Hypoxia Resulting in Murine Intrauterine Growth Restriction Parallels Increased Risk of Adult Cardiometabolic Disease.

Authors:  Alison Chu; David Casero; Shanthie Thamotharan; Madhuri Wadehra; Amy Cosi; Sherin U Devaskar
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

Review 8.  On the Relationship between Diabetes and Obstructive Sleep Apnea: Evolution and Epigenetics.

Authors:  N R C Wilson; Olivia J Veatch; Steven M Johnson
Journal:  Biomedicines       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.